ImmunityBio Inc (NASDAQ: IBRX)’s stock price has increased by 2679109 compared to its previous closing price of 2.87. However, the company has seen a -10.26% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-12 that ImmunityBio, Inc.’s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva’s indications could reach $900 million by 2028, implying a 73% upside, but this is far from guaranteed. The company’s lymphopenia treatment would face zero competition and would provide a larger addressable market.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
Moreover, the 36-month beta value for IBRX is -0.01. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IBRX is 91.82M and currently, short sellers hold a 78.54% of that float. On June 23, 2025, IBRX’s average trading volume was 9.38M shares.
IBRX’s Market Performance
IBRX’s stock has seen a -10.26% decrease for the week, with a 3.96% rise in the past month and a 1.66% gain in the past quarter. The volatility ratio for the week is 5.42%, and the volatility levels for the past 30 days are at 4.70% for ImmunityBio Inc The simple moving average for the past 20 days is -4.76% for IBRX’s stock, with a -17.67% simple moving average for the past 200 days.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with Piper Sandler repeating the rating for IBRX by listing it as a “Overweight.” The predicted price for IBRX in the upcoming period, according to Piper Sandler is $5 based on the research report published on May 20, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $8. The rating they have provided for IBRX stocks is “Buy” according to the report published on March 06th, 2025.
BTIG Research gave a rating of “Buy” to IBRX, setting the target price at $6 in the report published on January 10th of the current year.
IBRX Trading at 3.20% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.89% of loss for the given period.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -10.04 for the present operating margin
- 0.87 for the gross margin
The net margin for ImmunityBio Inc stands at -13.1. The total capital return value is set at -1.23.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated -0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -9.13. The debt to equity ratio resting at -0.07. The interest coverage ratio of the stock is -3.09.
Currently, EBITDA for the company is -241.76 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 76.67. The receivables turnover for the company is 1.83for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
To wrap up, the performance of ImmunityBio Inc (IBRX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
